// App-Quantinova.ai

2544 : Multi-Agent Chemotherapy Overcomes Steroid Resistance Conferred by a BIM Deletion Polymorphism in Pediatric Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Sheila Xinxuan Soh

Principal Investigators

  • Joshua Y.S. Lim

  • John W.J. Huang

  • Shirley K.Y. Kham

  • Allen E.J. Yeoh

  • S. Tiong Ong

Medical Centers

  • Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore, Singapore, Singapore

  • Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

  • Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore

  • Department of General Surgery, Singapore General Hospital, Singapore, Singapore

  • Cancer & Stem Cell Biology Signature Research Program, Duke-NUS Graduate Medical School, Singapore, Singapore

  • Viva-University Children's Cancer Centre, University Children's Medical Institute, National University Health System, Singapore, Singapore

  • Department of Radiation Oncology, Duke University Medical Center, Durham, NC

  • National University Cancer Institute, National University Health System, Singapore, Singapore, Singapore

Locations

  • United States

  • Singapore

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Myelogenous Leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Vincristine

  • Methadone hydrochloride

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved